RXSTNasdaqOphthalmic GoodsFiscal year ends December 31
RxSight, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$4.69+0.18 (+3.99%)
Close on Oct 19, 2026
- Market cap
- $194.59M
- P/E (TTM)
- –
- Dividend yield
- –
RxSight statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Ophthalmic Goods companies for comparison
Valuation
| Measure | RxSight | Industry median |
|---|---|---|
| Market Cap | $195.07M | $230.55M |
| Enterprise Value | -$13.73M | $202.97M |
| PS Ratio | 1.53 | 3.11 |
| PB Ratio | 0.74 | 3.14 |
| P/TBV Ratio | 0.74 | 4.57 |
Enterprise value
| Measure | RxSight | Industry median |
|---|---|---|
| EV / Sales | -0.11 | 2.92 |
Income (trailing twelve months)
| Measure | RxSight | Industry median |
|---|---|---|
| Revenue | $127.58M | $102.39M |
| Gross Profit | $98.87M | $60.36M |
| Operating Income | -$55.11M | -$4.31M |
| Pretax Income | -$46.84M | -$2.26M |
| Net Income | -$46.95M | -$6.57M |
| EBITDA | -$51.58M | -$1.98M |
| EPS (Diluted) | -$1.13 | -$0.07 |
Margins
| Measure | RxSight | Industry median |
|---|---|---|
| Gross Margin | 77.5% | 55.1% |
| Operating Margin | -43.2% | -6.04% |
| Pretax Margin | -36.7% | -4.11% |
| Profit Margin | -36.8% | -10.5% |
| EBITDA Margin | -40.4% | -2.67% |
| FCF Margin | -21.3% | -0.30% |
Returns
| Measure | RxSight | Industry median |
|---|---|---|
| Return on Equity (ROE) | -17.3% | -19.2% |
| Return on Assets (ROA) | -14.2% | -13.3% |
| Return on Invested Capital (ROIC) | -82.9% | -4.11% |
| Return on Capital Employed (ROCE) | -20.2% | -9.07% |
Growth
| Measure | RxSight | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -13.2% | 8.85% |
| Revenue Growth (3Y CAGR) | 40.0% | 7.08% |
| Revenue Growth (5Y CAGR) | 55.7% | 11.8% |
Balance sheet
| Measure | RxSight | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $208.80M | $37.33M |
| Net Cash (Debt) | $208.80M | $3.92M |
| Net Cash Per Share | $5.02 | $0.28 |
| Equity (Book Value) | $263.34M | $57.36M |
| Book Value Per Share | $6.33 | $2.81 |
| Tangible Book Value | $263.34M | $10.71M |
| Working Capital | $246.95M | $54.64M |
Financial position
| Measure | RxSight | Industry median |
|---|---|---|
| Current Ratio | 4.07 | 2.50 |
| Quick Ratio | 2.83 | 1.54 |
| Interest Coverage | -3674.27 | -1.81 |
Cash flow (trailing twelve months)
| Measure | RxSight | Industry median |
|---|---|---|
| Operating Cash Flow | -$22.73M | -$653.46K |
| Capital Expenditures | -$4.43M | -$3.69M |
| Free Cash Flow | -$27.17M | -$835.02K |
| FCF Per Share | -$0.65 | -$0.02 |
Efficiency
| Measure | RxSight | Industry median |
|---|---|---|
| Asset Turnover | 0.39 | 0.59 |
| Inventory Turnover | 0.92 | 2.21 |
| Revenue Per Employee | $276.75K | $322.57K |
| Profits Per Employee | -$101.84K | -$51.88K |
| Employee Count | 461 | 185 |
Dividends and yields
| Measure | RxSight | Industry median |
|---|---|---|
| Earnings Yield | -24.1% | -6.91% |
| FCF Yield | -13.9% | -0.56% |
| Buyback Yield | -1.03% | 0.78% |
| Shareholder Yield | -1.03% | 0.80% |
Shares
| Measure | RxSight | Industry median |
|---|---|---|
| Shares Outstanding | 41,593,300 | 44,856,700 |
| Shares Change (YoY) | 2.19% | 3.35% |
| Shares Change (QoQ) | 0.49% | 0.27% |
| Float | 39,359,100 | 37,097,900 |
| Shares Held by Insiders | 5.37% | 10.6% |
| Shares Held by Institutions | 99.6% | 63.5% |
Taxes
| Measure | RxSight | Industry median |
|---|---|---|
| Income Tax | $109.00K | $1.52M |
Scores
| Measure | RxSight | Industry median |
|---|---|---|
| Altman Z-Score | -0.74 | 1.95 |
| Piotroski F-Score | 3 | 5 |
| Beneish M-Score | -3.13 | -2.64 |
Calculated by StockData from RxSight's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.